// App-Quantinova.ai

e21666 : Effect of APF530 on health-related quality of life (QOL) and other chemotherapy-induced nausea and vomiting (CINV) end points: Phase III MAGIC trial.

Researchers

Presenter

  • Ian Schnadig

Principal Investigators

  • Eduardo Braun

  • Michael Mosier

  • Robert B. Geller

  • Lee Steven Schwartzberg

Medical Centers

  • Compass Oncology, US Oncology Research, Tualatin, OR

  • Michiana Hematology Oncology, Westville, IN

  • EMB Statistical Solutions, LLC., Overland Park, KS

  • Mirati Therapeutics Inc., San Diego, CA

  • West Clinic, Memphis, TN

Locations

  • United States

Companies

  • EMB Statistical Solu

  • Heron Therapeutics,

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chemotherapy-induced nausea and vomiting

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Fosaprepitant

  • granisetron tablet

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT02106494APF530

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved